Macrogen Europe expands sequencing capacity

Macrogen Europe expands sequencing capacity

Installation of additional high-throughput Illumina NovaSeq 6000 in Amsterdam result of increased demand for Macrogen’s sequencing services

Amsterdam, The Netherlands, 18 May 2021 – Genomic sequencing service provider Macrogen Europe has achieved a significant upgrade to its next generation sequencing (NGS) capacity. The installation of an additional Illumina NovaSeq 6000 high-throughput sequencing system in its headquarters in the Netherlands helps manage increased demand with high-quality results and fast, reliable turnaround times.

The addition of the new NovaSeq 6000 to Macrogen Europe’s range of industry-leading NGS and Sanger sequencing platforms comes at time of growing demand for its DNA sequencing services, for example from biomarker and drug discovery applications in oncology, immunology and metagenomics. The increased sequencing capacity helps clients in industry, academia and research institutes keep their projects on track.

High capacity and flexibility are the key drivers for choosing the NovaSeq 6000. The additional capability enables Macrogen Europe to sequence 96 human whole genomes or 1000 whole exomes in two days. Macrogen Europe supports clients on projects of all different sizes, and its portfolio of sequencing equipment is optimized to ensure every sample can be analyzed efficiently and with the most suitable equipment.

“We always want to make sure we deliver each project with the quality and speed clients expect from us,” says Junho Kook, lab manager at Macrogen Europe, commenting on the news. “In the past year, we’ve seen significant growth in the number of samples to be processed in Europe – and this increase in capacity means we are ready to grow further without compromise.” Macrogen Europe’s CEO, Bongcho Kim, added: “This expansion forms a significant milestone in our strategy to increase and broaden our offering with new sequencing platforms, IT infrastructure and bioinformatics pipelines. This, together with our growing team, means we don’t just deliver data to our clients, but also expert scientific, technical and bioinformatics support for close collaborations that help make every sequencing project a success.”

With over 20 years’ experience of providing high-quality genomic sequencing services, Macrogen is an established global sequencing leader. It opened a European branch office at the Amsterdam Medical Center (AMC) in the Netherlands in 2008, which became a subsidiary, Macrogen Europe BV, in 2017. It uses the latest technology from industry-leading suppliers such as Illumina, Pacific Biosciences and Thermo Fisher Scientific to deliver fast, accurate results to researchers and industry professionals across Europe and Africa.

For more information, please visit macrogen-europe.com.

ABOUT: Macrogen Europe BV is a leading provider of Sanger sequencing, next generation sequencing (NGS) and bioinformatics services for scientists in academia, clinical research and industry. Macrogen Europe provides flexible, fast sequencing of DNA and RNA with comprehensive, reliable data. Its services are available across Europe and Africa and include whole genome, whole exome and targeted sequencing – as well as transcriptome, epigenome, metagenome and single cell sequencing.

Macrogen Europe BV’s services are for research use only (RUO). Not for use in diagnostic procedures.